journal
https://read.qxmd.com/read/38644097/bacterial-vaccines-for-the-management-of-recurrent-urinary-tract-infections-a-systematic-review-and-meta-analysis
#1
REVIEW
Quentin Mak, Julian Greig, Prokar Dasgupta, Sachin Malde, Nicholas Raison
BACKGROUND AND OBJECTIVE: Several bacterial immunisations have been developed to reduce the socioeconomic burden of urinary tract infections (UTIs) and the use of prophylactic antibiotics in the management of recurrent UTIs (rUTIs). This systematic review evaluates the effectiveness of vaccinations in preventing rUTIs. METHODS: Medline, Embase, and Web of Science were searched from inception to December 2023. Data were collected from cohort studies with a comparator arm and randomised controlled trials (RCTs) investigating vaccination efficacy in adult rUTI patients according to predefined selection criteria (PROSPERO registration: CRD42022356662)...
April 20, 2024: European Urology Focus
https://read.qxmd.com/read/38631992/a-systematic-review-on-the-impact-of-quality-assurance-programs-on-outcomes-after-radical-prostatectomy
#2
REVIEW
Sophia H van der Graaf, Marinus J Hagens, Hans Veerman, Ton A Roeleveld, Jakko A Nieuwenhuijzen, Esther M K Wit, Michel W J M Wouters, Stevie van der Mierden, R Jeroen A van Moorselaar, Harrie P Beerlage, André N Vis, Pim J van Leeuwen, Henk G van der Poel
BACKGROUND AND OBJECTIVE: The implementation of quality assurance programs (QAPs) within urological practice has gained prominence; yet, their impact on outcomes after radical prostatectomy (RP) remains uncertain. This paper aims to systematically review the current literature regarding the implementation of QAPs and their impact on outcomes after robot-assisted RP, laparoscopic RP, and open prostatectomy, collectively referred to as RP. METHODS: A systematic Embase, Medline (OvidSP), and Scopus search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process, on January 12, 2024...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38631991/biomarkers-of-response-to-anti-nectin4-antibody-drug-conjugate-enfortumab-vedotin-in-urothelial-cancer
#3
REVIEW
Niklas Klümper, Markus Eckstein
Initial studies indicated that NECTIN4 expression is widespread in metastatic urothelial cancer (mUC), which led to approval of the anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) for unselected patients with mUC. However, the recent literature suggests that there has been overestimation of membranous NECTIN4 expression in UC, which is a prerequisite for EV binding. It is well established from the development of Her2-targeting ADCs that treatment response is strongly dependent on membranous expression level of the relevant target antigen...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38627124/results-at-1-year-from-saturn-a-european-prospective-multicenter-registry-for-male-stress-urinary-incontinence-surgery
#4
JOURNAL ARTICLE
John Heesakkers, Frank Martens, Nikesh Thiruchelvam, Wim Witjes, Christien Caris, Joni Kats, Rizwan Hamid, Frank Van der Aa
BACKGROUND AND OBJECTIVE: The European, prospective, multicenter SATURN registry was developed to analyze surgical devices for male stress urinary incontinence. The primary objective is the cure rate during follow-up. METHODS: Efficacy, complications, patient-reported outcomes, and prognostic factors are being analyzed at various intervals during 10-yr follow-up. The results at 1-yr follow-up are presented here. KEY FINDINGS AND LIMITATIONS: The cohort included 1046 patients (mean age 70 yr) from 28 centers in nine countries...
April 15, 2024: European Urology Focus
https://read.qxmd.com/read/38600021/promoting-green-in-person-scientific-conferences
#5
LETTER
Pietro Diana, Benjamin Pradere, Alessandro Uleri, Michael Baboudjian
No abstract text is available yet for this article.
April 9, 2024: European Urology Focus
https://read.qxmd.com/read/38582643/front-line-platinum-continues-to-have-a-role-in-advanced-bladder-cancer
#6
JOURNAL ARTICLE
Ursula M Vogl, Irene Testi, Maria De Santis
Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
April 5, 2024: European Urology Focus
https://read.qxmd.com/read/38582642/re-narek-shaverdian-and-reshma-jagsi-when-headlines-harm-patients-with-cancer-jama-oncol-2023-9-1611-2
#7
LETTER
Francesco Montorsi, Marco Moschini, Mario de Angelis, Alberto Briganti, Andrea Gallina, Nazareno Suardi, Federico Dehò
No abstract text is available yet for this article.
April 5, 2024: European Urology Focus
https://read.qxmd.com/read/38580524/impact-of-synchronous-versus-metachronous-metastasis-on-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-first-line-immune-checkpoint-inhibitor-based-combinations
#8
JOURNAL ARTICLE
Georges Gebrael, Luis Meza, Xiaochen Li, Zeynep Zengin, Nicolas Sayegh, Hedyeh Ebrahimi, Nishita Tripathi, Daniela Castro, Benjamin Mercier, Regina Barragan-Carrillo, Haoran Li, Alexander Chehrazi-Raffle, Umang Swami, Abhishek Tripathi, Neeraj Agarwal, Benjamin L Maughan, Sumanta K Pal
BACKGROUND AND OBJECTIVE: The impact of time of metastasis onset with respect toprimary renal cell carcinoma (RCC) diagnosis on survival outcomes is not well characterized in the era of immune checkpoint inhibitor (ICI)-based combinations. Herein, we assessed differences in clinical outcomes between synchronous and metachronous metastatic RCC (mRCC). METHODS: Data for patients with mRCC treated with first-line ICI-based combination therapies between 2014 and 2023 were retrospectively collected...
April 4, 2024: European Urology Focus
https://read.qxmd.com/read/38531756/prostatic-artery-embolisation-versus-transurethral-resection-of-the-prostate-for-benign-prostatic-obstruction-5-year-outcomes-of-a-randomised-open-label-noninferiority-trial
#9
JOURNAL ARTICLE
Gautier Müllhaupt, Lukas Hechelhammer, Nicole Graf, Livio Mordasini, Hans-Peter Schmid, Daniel S Engeler, Dominik Abt
BACKGROUND AND OBJECTIVE: Prostatic artery embolisation (PAE) and transurethral resection of the prostate (TURP) are two of the surgical options for treatment of lower urinary tract symptoms/benign prostatic obstruction (LUTS/BPO). Our aim was to compare the efficacy and safety of PAE and TURP for LUTS/BPO treatment at long-term follow-up. METHODS: We conducted a randomised, open-label, single-centre trial at a Swiss tertiary care centre. The main outcome was the change in International Prostate Symptom Score (IPSS) after PAE versus TURP...
March 25, 2024: European Urology Focus
https://read.qxmd.com/read/38508896/sterile-water-versus-glycine-in-transurethral-resection-of-bladder-tumors-immunogenic-and-clinical-implications
#10
JOURNAL ARTICLE
Haim Herzberg, Roi Babaoof, Ron Marom, Yotam Veredgorn, Ziv Savin, Karin Lifshitz, Shmulik Noefeld, Rinat Lasmanovitz, Shayel Bercovich, Tomer Lamhoot, Sharon Amir, Avi Beri, David Margel, Jack Baniel, Roy Mano, Ofer Yossepowitch
BACKGROUND AND OBJECTIVE: We compared the oncologic outcomes of patients with non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TUBRT) using sterile water vs glycine irrigation. The tumoricidal and immunogenic effects of these solutions on urothelial cancer cell lines were investigated. METHODS: The medical records of 530 consecutive patients who underwent TURBT using sterile water or glycine irrigation for NMIBC were reviewed...
March 19, 2024: European Urology Focus
https://read.qxmd.com/read/38508895/transperineal-or-transrectal-magnetic-resonance-imaging-targeted-biopsy-for-prostate-cancer-detection
#11
JOURNAL ARTICLE
Romain Diamand, Karsten Guenzel, Georges Mjaess, Yolène Lefebvre, Mariaconsiglia Ferriero, Giuseppe Simone, Alexandre Fourcade, Georges Fournier, Alexandre-Patrick Bui, Fayek Taha, Marco Oderda, Paolo Gontero, Katerina Rysankova, Adrian Bernal-Gomez, Alessandro Mastrorosa, Jean-Baptiste Roche, Gaelle Fiard, Rawad Abou Zahr, Guillaume Ploussard, Olivier Windisch, Quentin Novello, Daniel Benamran, Gina Delavar, Julien Anract, Nicolas Barry Delongchamps, Adam Halinski, Charles Dariane, Jan Benijts, Gregoire Assenmacher, Thierry Roumeguère, Alexandre Peltier
BACKGROUND AND OBJECTIVE: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the lower risk of severe urinary tract infections. The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx. METHODS: Patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for clinically localized PCa at 15 European referral centers from 2016 to 2023 were included...
March 19, 2024: European Urology Focus
https://read.qxmd.com/read/38493068/re-rano-matta-refik-saskin-sarah-neu-et-al-predicting-mirabegron-treatment-response-in-patients-with-overactive-bladder-a-post-hoc-analysis-of-data-from-clinical-trials-eur-urol-focus-2023-9-957-65
#12
LETTER
https://read.qxmd.com/read/38493067/feasibility-of-next-generation-sequencing-of-liquid-biopsy-circulating-tumor-dna-samples-and-tumor-tissue-from-patients-with-metastatic-prostate-cancer-in-a-real-world-clinical-setting-in-germany
#13
JOURNAL ARTICLE
Philipp Mandel, Benedikt Hoeh, Clara Humke, Claudia Doering, Mike Wenzel, Cristina Cano Garcia, Nina Fuhr, Florestan Koll, Anne Fassl, Derya Tilki, Thomas Steuber, Iris Faull, Jan Jeroch, Silvana Ebner, Christina Schmitt, Henning Reis, Jens Köllermann, Konstantinos D Kokkaliaris, Melanie C Demes, Felix K H Chun, Peter J Wild
BACKGROUND AND OBJECTIVE: With European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer and ongoing trials in metastatic hormone-sensitive prostate cancer, detection of genetic alterations in BRCA1/2 and other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility and comparability of comprehensive next-generation sequencing (NGS) of liquid biopsy (LB; circulating tumor DNA) and tumor tissue (TT) samples in a real-world clinical setting...
March 15, 2024: European Urology Focus
https://read.qxmd.com/read/38453584/radical-prostatectomy-for-nonmetastatic-prostate-cancer-in-renal-transplant-recipients-outcomes-for-a-large-contemporary-cohort-and-a-matched-comparison-to-patients-without-a-transplant
#14
JOURNAL ARTICLE
Giancarlo Marra, Stefano Tappero, Francesco Barletta, Alessandro Marquis, Marco Allasia, Marco Oderda, Charles Dariane, Marc-Olivier Timsit, Julien Branchereau, Benoit Mesnard, Derya Tilki, Jonathon Olsburgh, Meghana Kulkarni, Veeru Kasivisvanathan, Cedric Lebacle, Alberto Breda, Antonio Galfano, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Luigi Biancone, Paolo Gontero
BACKGROUND AND OBJECTIVE: It is unknown whether renal transplant receipt (RTR) status can affect perioperative and oncological outcomes of radical prostatectomy (RP). Our aim was to evaluate oncological and functional outcomes of RTR patients treated with RP for cN0M0 prostate cancer (PCa) via comparison with a no-RTR cohort. METHODS: RTR patients who had undergone RP at seven European institutions during 2001-2022 were identified. A multi-institutional cohort of no-RTR patients treated with RP during 2004-2022 served as the comparator group...
March 6, 2024: European Urology Focus
https://read.qxmd.com/read/38433067/the-impact-of-venous-thromboembolism-on-upper-tract-urothelial-carcinomas-undergoing-open-or-minimally-invasive-radical-nephroureterectomy-in-the-usa-perioperative-outcomes-and-health-care-costs-from-insurance-claims-data
#15
JOURNAL ARTICLE
Anas S Tresh, Francesco Del Giudice, Shufeng Li, Satvir Basran, Federico Belladelli, Ettore De Berardinis, Vincenzo Asero, Matteo Ferro, Sabin Tataru, Gian Maria Busetto, Ugo Falagario, Riccardo Autorino, Felice Crocetto, Biagio Barone, Benjamin Pradere, Marco Moschini, Andrea Mari, Wojciech Krajewski, Łukasz Nowak, Bartosz Małkiewicz, Tomasz Szydełko, Simone Crivellaro, Abhay Rane, Benjamin Challacombe, Rajesh Nair, Benjamin I Chung
BACKGROUND AND OBJECTIVE: Venous thromboembolism (VTE) is a significant predictor of worse postoperative morbidity in cancer surgeries. No data have been available for patients with preoperative VTE and upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). Our aim was to assess the impact of a preoperative VTE diagnosis on perioperative outcomes in the RNU context. METHODS: Patients aged 18 yr or older with a UTUC diagnosis undergoing RNU were identified in the Merative Marketscan Research deidentified databases between 2007 and 2021...
March 2, 2024: European Urology Focus
https://read.qxmd.com/read/38402105/opportunistic-prostate-cancer-screening-with-biparametric-magnetic-resonance-imaging-visioning
#16
JOURNAL ARTICLE
Christian Wetterauer, Mark Matthias, Heike Pueschel, Alexander Deckart, Lukas Bubendorf, Ashkan Mortezavi, Emilio Arbelaez, David Jean Winkel, Tobias Heye, Daniel T Boll, Elmar Merkle, Stefanie Hayoz, Helge H Seifert, Cyrill A Rentsch
BACKGROUND: This study investigates the use of biparametric magnetic resonance imaging (bpMRI) as primary opportunistic screening for prostate cancer (PCa) without using a prostate-specific antigen (PSA) cut-off. OBJECTIVE: The primary endpoint was to assess the efforts and effectiveness of identifying 20 participants with clinically significant prostate cancer (csPCa) using bpMRI. DESIGN, SETTING, AND PARTICIPANTS: Biopsy-naïve men aged over 45 yr were included...
February 23, 2024: European Urology Focus
https://read.qxmd.com/read/38402104/a-double-blind-randomised-four-way-crossover-study-to-compare-the-effects-of-fesoterodine-4-and-8-mg-once-daily-and-qxybutynin-5-mg-twice-daily-after-steady-state-dosing-versus-placebo-on-cognitive-function-in-overactive-bladder-wet-patients-over-the-age-of
#17
JOURNAL ARTICLE
Saima Rajabali, Prosper Asaana, Sahar Nazari, Adrian Wagg
BACKGROUND AND OBJECTIVE: There is a reported association between overactive bladder (OAB) treated with antimuscarinic drugs and an increased risk of a dementia diagnosis, although short-term data suggest that newer OAB antimuscarinics are cognitively safe. This study examined the cognitive safety of fesoterodine in older adults with mild cognitive impairment (MCI) and OAB. METHODS: This four-way randomised crossover study examined the cognitive effects of fesoterodine 4 and 8 mg and oxybutynin 5 mg b...
February 23, 2024: European Urology Focus
https://read.qxmd.com/read/38395728/urologists-and-sustainability-the-first-survey-from-the-french-sustainability-working-group
#18
LETTER
Michael Baboudjian, Alexandre de La Taille, Eric Lechevallier, Benjamin Pradere, Richard Mallet
No abstract text is available yet for this article.
February 22, 2024: European Urology Focus
https://read.qxmd.com/read/38388216/introducing-washout-a-large-scale-observational-study-of-inpatient-haematuria
#19
EDITORIAL
Kevin G Byrnes, Nikita R Bhatt, Simona Ippoliti, Raghav Varma, Aqua Asif, Nikki Kerdegari, Arjun Nathan, Kevin Gallagher, Sinan Khadhouri, Veeru Kasivisvinathan
WASHOUT is an international, multicentre, prospective observational study aiming to describe the management of unscheduled haematuria admissions. Preregistration can be done using the following link: https://redcap.link/WASHOUT.
February 21, 2024: European Urology Focus
https://read.qxmd.com/read/38388215/risks-of-dementia-after-treatment-with-an-anticholinergic-beta-3-agonist-or-combination-of-both-for-an-overactive-bladder-a-korean-national-cohort-study
#20
JOURNAL ARTICLE
Jee Soo Park, Soo Beom Choi, Won Sik Jang, Jongchan Kim, Won Sik Ham
BACKGROUND AND OBJECTIVE: An overactive bladder (OAB) is primarily managed with behavioural therapy and using anticholinergics and beta-3 agonists. Reports have shown that the use of anticholinergics by OAB patients was associated with an increased risk of new-onset dementia compared with those using beta-3 agonists. This study compares the risks of dementia among patients with an OAB starting on a beta-3 agonist alone, an anticholinergic alone, or a combination treatment. METHODS: Using data from the Korean National Health Insurance Service database, we studied a nationwide population cohort comprising patients newly diagnosed with an OAB who initiated their OAB medications between 2015 and 2020...
February 21, 2024: European Urology Focus
journal
journal
52364
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.